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Objectives. The objectives of this study were to determine
whether a signal-averaged electrocardiogram (SAECG) or mea-
surement of interlead variability of QT intervals on an electrocar-
diogram (ECG) obtained at the time of wait-listing could provide
prognostic value with respect to cardiac death during the waiting
period.
Background. Because heart transplantation is a life-saving but
limited resource, there remains an urgent need to identify those
patients at greatest risk of dying while awaiting heart transplan-
tation as part of the strategy to optimize the allocation of donor
organs to those in greatest need. This study was undertaken to
prospectively identify clinical, ECG or SAECG variables that
might predict mortality during the waiting period.
Methods. Of 108 consecutive patients referred for heart trans-
plant evaluation, 80 were placed on a waiting list, at which time a
standard 12-lead ECG and a SAECG were recorded. In this cohort
of 80 patients, QT dispersion was characterized from the 12-lead
ECG as either the maximal–minimal QT interval (QTDISP) or as
the coefficient of variation of all QT intervals (QTCV).
Results. During the 25-month follow-up period (mean time on
waiting list, 201 days), the mortality rate was 27%/year, divided
equally between heart failure and sudden deaths. No clinical
variable identified at entry predicted mortality. QTDISP and
QTCV were strong mortality predictors, with a 4.1-fold increase in
mortality in patients with QTDISP >140 ms compared with those
patients with QTDISP <2140 ms (95% CI 1.1 to 14.9), whereas a
QTCV >29% also predicted a 4.1-fold increased risk of death (95%
CI 1.4 to 11.8). Although 88% of all SAECGs were abnormal, no
patient with a normal SAECG died suddenly during the waiting
period.
Conclusions. Indexes of QT dispersion provide a means of strati-
fying a patient’s risk of dying while awaiting heart transplantation
and may help to establish priority on a heart transplant waiting list.
(J Am Coll Cardiol 1997;29:1576–84)
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Patients with end-stage heart failure can have a 40% one-year
mortality rate, with an annual incidence of sudden death in
outpatients exceeding 25% (1,2). Heart transplantation is
often life-saving in these high risk patients, but many patients
who are accepted as candidates for heart transplantation die
while awaiting the transplant. Because only one in 10 patients
who would benefit from transplantation actually receives a
heart, owing to the shortage of donor organs, and because of
the high mortality while awaiting transplantation, it would be
advantageous to identify those patients at highest risk of dying
during the waiting period to help establish priority on a heart
transplant waiting list. In addition, each month twice as many
patients are listed for transplantation as those who actually
receive hearts, and waiting time for hearts has increased (3),
with hearts preferentially going to deteriorating inpatient
candidates (4,5). Thus, it becomes imperative not only to
identify patients (especially outpatients) at high risk of dying
during the waiting period, but also to identify low risk patients
as part of the national strategy to optimize use of heart
transplantation as a limited medical resource.
Many prognostic factors for poor outcome have been
identified in patients with heart failure, including depressed
left ventricular ejection fraction, low serum sodium, high levels
of neurohormonal activation, advanced New York Heart As-
sociation functional class and limited exercise tolerance (6–
10). More limited data have been available with respect to
patients with severe heart failure who await heart transplanta-
tion. Sudden death of these patients is a vexing problem, and
there exists no definitive means of predicting which patients
may die suddenly, as opposed to those who succumb to
progressive deterioration of ventricular function. Although a
normal signal-averaged electrocardiogram (SAECG) (11–14)
and the absence of inducible sustained arrhythmias by pro-
grammed electrical stimulation (15) may be associated with a
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low incidence of sudden death in patients with dilated cardio-
myopathy, it is unclear whether these tests are useful in
predicting which patients who are ill enough to require heart
transplantation can survive the waiting period to receive a
donor heart.
Recent studies have suggested that a standard 12-lead
electrocardiogram (ECG) can provide prognostic information
in some patient cohorts, especially when related to measure-
ments of ventricular repolarization. Although QT prolongation
appears to predict cardiovascular mortality in many patients
(16–18), including apparently healthy individuals (19), it is not
predictive in patients with left ventricular dysfunction (20).
There has been a recent burgeoning interest in measuring the
heterogeneity of repolarization times across the ventricular
myocardium, using QT dispersion, which can be measured as
the interlead variability of QT intervals on the 12-lead ECG.
QT dispersion has been shown to predict sudden death in
several patient cohorts, including those who are postmyocar-
dial infarction (21) and those with ischemic cardiomyopathy
(22). However, the predictive value of QT dispersion in a
diverse group of patients with heart failure or those awaiting
heart transplantation has not been evaluated.
Because patients accepted as candidates for heart trans-
plantation represent a select group of patients who often do
not survive the waiting period for a donor heart, there remains
an urgent need to prospectively identify risk factors (at the
time of heart transplant evaluation) to help assign transplant
priority. This study was undertaken to determine whether
clinical, ECG or SAECG variables obtained at the time of
placement on the waiting list can be used to identify patients
with an elevated risk of dying during the waiting period before
heart transplantation. Identification of noninvasive, easily ob-
tainable positive or negative predictors of risk could improve
the strategy for allocation of the limited supply of donor
organs, thereby reducing waiting lists and improving survival
during the waiting period.
Methods
Patient selection. Over an 11-month period, 108 consecu-
tive patients referred for heart transplant evaluation were
asked to participate in this study, before any decision was made
regarding their acceptability as a transplant candidate. Patients
were enrolled after obtaining written informed consent to
participate in this protocol, approved by the Institutional
Review Board at Columbia–Presbyterian Medical Center.
Baseline clinical variables were recorded at the time of initial
evaluation, based on interviewing the patient and review of the
medical records. In addition, a standard 12-lead ECG and a
SAECG were obtained. Decisions regarding the patients’
acceptability as heart transplant candidates (as well as deci-
sions to remove patients from active status on the waiting list)
were made independently by the heart transplant team.
12-Lead ECGs and measurement of QT dispersion. On
enrollment into the protocol, standard 12-lead ECGs were
obtained at a paper speed of 25 mm/s. Heart rate, QRS
duration and QT intervals were measured from hard copies of
the baseline ECG without knowledge of outcome data. QT
intervals (23,24) were measured from the beginning of the
inscription of the QRS complex until the T wave returned to
the isoelectric line. If a U wave was present, the nadir of the T
wave was identified as the termination of the QT interval.
Rarely, notched or diphasic T waves were differentiated from
T-U fusion waves. The following criteria were used (25): 1) U
waves have their largest amplitude in leads V2 and V3; 2) U
waves have ,25% of the largest T wave amplitude in 98% of
cases and ,50% of the T wave amplitude in the same lead; 3)
U wave voltage varies directly with T wave voltage; 4) U wave
polarity, timing and voltage are similar when compared in
contiguous leads; 5) there is typically a sudden change in slope
with a notch at the T-U junction; and 6) T and U apices are
separated by .0.15 s, whereas apices of diphasic T waves are
,0.15 s apart. Measurements were not obtained from leads in
which termination of the T wave could not be clearly identified
(i.e., where isoelectric), but in all cases, a minimum of six leads
were measured (ECGs were technically uninterpretable in two
patients). QT dispersion was classified according to two meth-
ods (26). QT dispersion (QTDISP) was the difference between
the maximal and the minimal QT intervals measured on the
12-lead ECG. The coefficient of variation of QT intervals
(QTCV) was calculated according to the formula QTCV 5
100 3 (standard deviation of QT intervals/mean QT interval).
The corrected QT interval (QTc) was determined according to
Bazett’s formula (27): QTc 5 QT/=RR interval. QTc disper-
sion was calculated in a similar fashion as QTDISP, but was
corrected for the RR interval. For patients with atrial fibrilla-
tion, the QT interval was measured from the first complex of
each group of three simultaneously acquired ECG leads.
Signal-averaged ECGs. The SAECGs were recorded from
three orthogonal leads with a Corazonix Predictor system,
using silver-silver chloride electrodes. QRS complexes were
accepted after screening by a template recognition program,
and acquisition continued until noise was reduced ,0.3 mV.
For each SAECG obtained, three variables were analyzed after
40- to 250-Hz bandpass bidirectional filtering (28,29) to iden-
tify late potentials. These variables included 1) the filtered
QRS duration (fQRS, ms), measured from the vector magni-
tude of the filtered leads expressed as the square root of the
Abbreviations and Acronyms
BBB 5 bundle branch block
ECG 5 electrocardiogram, electrocardiographic
fQRS 5 filtered QRS
IVCD 5 intraventricular conduction
LAS 5 low amplitude signal at terminal portion of QRS complex
QTc 5 corrected QT interval
QTCV 5 coefficient of variation of QT intervals
QTDISP 5 QT dispersion
SAECG 5 signal-averaged electrocardiogram
V40 5 voltage of terminal 40 ms of QRS complex
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sum (X2 1 Y2 1 Z2); 2) the voltage of the terminal 40 ms
(V40) of the fQRS complex (mV); and 3) the duration of low
amplitude (,40 mV) signal (LAS) at the terminal portion of
the fQRS complex (ms). Criteria for normal SAECG variables
were as follows (30): 1) fQRS ,110 ms; 2) V40 .20 mV; and
3) LAS ,38 ms. In addition to performing outcome analyses
using SAECGs from all patients awaiting heart transplanta-
tion, separate analyses were performed using those SAECGs
from patients without an underlying bundle branch block
(BBB) or intraventricular conduction defect (IVCD; judged to
be present if the QRS complex exceeded 12 ms in duration).
Follow-up. Patients accepted as candidates for heart trans-
plantation were followed for up to 25 months from the
beginning of the study. For this cohort of patients accepted as
heart transplant candidates, the primary end point was defined
as cardiac death while awaiting heart transplantation. Addi-
tional end points were also identified, including the combined
end point of “cardiac death or urgent transplantation” (these
were patients transplanted as United Network for Organ
Sharing (UNOS) status I [i.e., in the intensive care unit on
inotropic support]), as well as transplantation or removal from
active status on the waiting list. These end points were
obtained by review of medical records, discussion with primary
physicians and interviews with family members and/or friends
concerning the circumstances of death. As a secondary end
point, cause of death was identified as follows: Sudden death
was defined as death within 1 h of the onset of new symptoms
in an outpatient with previously stable symptoms (31). Con-
gestive heart failure death was defined as progressive heart
failure symptoms leading to death with or without hospitaliza-
tion.
Statistics. Kaplan-Meier survival curves were computed,
and univariate and multivariate analyses were performed using
the log-rank test to assess the contributions of each variable
evaluated with respect to outcome. All statistics were calcu-
lated based on the number of days spent on the transplant
waiting list, including the time spent on the waiting list by
patients who were subsequently removed from active status.
Data are expressed as mean value 6 SD, with p , 0.05
considered statistically significant. Where appropriate, odds
ratios are given along with the 95% confidence interval (CI).
Results
Patients. The patient group consisted of 108 consecutive
patients who were referred to the heart transplant service.
Twenty-eight patients were not accepted as candidates for
transplantation for the following reasons: 10 were deemed to
be too well; five refused; four had concomitant diseases that
precluded transplantation; five were turned down because of
psychosocial reasons; one died before evaluation; and three
failed to follow-up with the transplant service. The remaining
80 patients were accepted as candidates for heart transplanta-
tion and were placed on a waiting list. These 80 patients were
followed up to 25 months and consisted of 63 men and 17
women (mean age 51 6 8 years, range 25 to 67). The majority
of patients (90%) were classified in functional class III heart
failure by the heart transplant service. The cause of heart
failure was ischemic in 44 (55%), idiopathic dilated cardiomy-
opathy in 33 (41%), valvular in 1 (1%) and congenital in 2
(3%). Thirteen patients were identified as having atrial fibril-
lation (17%). Mean left ventricular ejection fraction, deter-
mined by radionuclide or contrast ventriculography, was 19 6
10%. Twelve patients had a history of sustained ventricular
tachyarrhythmia (6 sustained ventricular tachycardia, 6 cardiac
arrest), 7 had a history of syncope, and 25 were receiving
antiarrhythmic therapy at the discretion of their primary
physician (type IA in 11 patients, type IB in 10, combination
IA/IB in 1 and type III in 3). One patient had an automatic
implantable cardiovertor defibrillator, and seven were receiv-
ing beta-blockers.
Patient outcome. Of the 80 patients placed on the trans-
plant waiting list, by the conclusion of this study at 25 months,
52 received a heart transplant (18 urgently as UNOS status I),
14 died while waiting, 13 were removed from the waiting list
and 1 remained on the active waiting list. The 13 patients who
were removed from active status were removed for various
reasons, including improved clinical status (n 5 5), patient
request (n 5 2), psychosocial reasons (n 5 1), other illness
(n 5 1) and failure to follow up with the transplant clinic (n 5
4). Of these patients, four were lost to follow-up, four died and
five remained alive by the end of 4 years. For patients accepted
as candidates for heart transplantation, the mean time on the
waiting list was 201 days, and therefore the actuarial mortality
rate was 27% per year during the period while awaiting heart
transplantation. Mortality was high and progressive during the
waiting period; by 1 month, 4% had died; by 3 months, 12%
had died; by 6 months, 18% had died; and at 12 months, 27%
had died (Fig. 1). Of the 14 deaths, seven were classified as
sudden and seven were considered deaths due to progressive
heart failure. No noncardiac deaths were identified.
Figure 1. Survival in 80 patients awaiting heart transplantation (at
time 0). All-cause mortality is shown, as well as cause-specific mortal-
ity. Congestive heart failure and sudden death were defined as
described in the Methods section.
1578 PINSKY ET AL. JACC Vol. 29, No. 7
RISK OF DYING WHILE AWAITING HEART TRANSPLANTATION June 1997:1576–84
Risk factor analysis. Clinical variables. None of the clini-
cal variables evaluated (including gender, etiology of heart
failure, functional class, history of ventricular tachyarryhthmias
or antiarrhythmic therapy) predicted either total (Table 1) or
cause-specific mortality while on the waiting list. Of the seven
patients who died suddenly, one had a history of ventricular
tachyarrhythmias and two were receiving antiarrhythmic ther-
apy. Although when evaluated as a continuous variable, age
did not predict mortality risk, the mean age of those who died
awaiting transplantation (55 6 5 years) was greater than that of
patients who survived the waiting period (50 6 8 years) (p 5
0.05). Left ventricular ejection fractions were uniformly low
(mean 19 6 10%) and did not predict either total or cause-
specific mortality.
Standard 12-lead ECG measurements. Variables identified
on the 12-lead ECG, including heart rate, QRS duration,
presence of BBB, absolute value of the QT interval or the QTc,
were not predictive of either total or cause-specific mortality
during the waiting period (Table 2). Atrial fibrillation, which
was identified in 17% of the patients awaiting heart transplan-
tation, was not a predictor of mortality in this series (Table 3).
Measurements of QT dispersion. In sharp contrast with
standard measurements obtained from the 12-lead ECG, mea-
surements of interlead variability of the QT interval were
strong mortality predictors (Table 2). QTDISP and QTCV as
continuous variables were highly predictive of mortality (p 5
0.009 and p 5 0.001, respectively). When patients were dichot-
omized into two groups—those with QTDISP #140 ms (short
QTDISP group, n 5 72) or those with QTDISP .140 ms (long
QTDISP group, n 5 6), the 1-year mortality differences were
striking (24% vs. 56%, respectively; odds ratio 4.1, 95% CI 1.1
to 14.9) (Fig. 2A). Patients whose QTCV was .9% (long
QTCV group, n 5 15) had a 4.1-fold increased mortality
compared with those whose QTCV was #9% (short QTCV
group, n 5 63) (95% CI 1.4 to 11.8) (Fig. 2B). (These cutpoints
for long and short QTDISP and QTCV were selected by post
hoc data analysis to yield predictive capability similar to that
observed using continuous variables [determined by the chi-
square test] after these variables were established to be
mortality predictors when evaluated as continuous variables.)
When the combined end point of “death or urgent transplan-
tation” was used for analysis, QTDISP and QTCV were each
significant predictors of mortality when viewed as continuous
variables (p 5 0.016 and p 5 0.010, respectively).
When short and long QTDISP groups were compared, no
significant differences were observed with respect to age,
Table 1. Clinical Characteristics of Patients Awaiting
Heart Transplantation
All Wait-
Listed Pts
(n 5 80)
Survived
(n 5 66)
Died
(n 5 14)
Age (yr) 51 6 8 50 6 8 55 6 5*
Men 63 (79%) 51 (77%) 12 (86%)
Etiology
Congenital 2 (3%) 2 (3%) 0 (0%)
Valvular 1 (1%) 0 (0%) 1 (7%)
Idiopathic 33 (41%) 28 (42%) 5 (36%)
Ischemic 44 (55%) 36 (55%) 8 (57%)
NYHA functional class
II 5% 5% 0%
III 90% 90% 100%
IV 5% 5% 0%
AF 17% 14% 3%
LVEF 19 6 10% 20 6 9% 19 6 11%
Previous VTs 12 (15%) 11 (17%) 1 (7%)
Antiarrhythmic therapy 25 (31%) 20 (30%) 5 (36%)
*p 5 0.05. Data presented are mean value 6 SD or number (%) of patients
(Pts). AF 5 atrial fibrillation; LVEF 5 left ventricular ejection fraction;
NYHA 5 New York Heart Association; Pts 5 patients; VTs 5 ventricular
tachyarrhythmias.
Table 2. Electrocardiographic Characteristics of Patients Awaiting Heart Transplantation
All Wait-Listed Pts
(n 5 80)
Survived
(n 5 66)
Died
(n 5 14)
HR (beats/min) 83 6 18 (44–123) 83 6 18 (44–123) 85 6 17 (46–114)
QRS complex (ms) 133 6 32 (72–200) 134 6 32 (72–200) 126 6 30 (92–180)
QRS complex (ms)* 102 6 11 (72–120) 102 6 12 (72–120) 99 6 6 (92–108)
QT interval (ms) 416 6 59 (308–627) 420 6 60 (308–627) 399 6 53 (310–489)
QTc interval (ms) 481 6 45 (405–604) 484 6 44 (415–604) 469 6 51 (405–587)
QT dispersion (ms) 89 6 39 (20–220) 85 6 34 (20–170) 112 6 51 (50–220)†
QTc dispersion (ms) 103 6 42 (22–238) 98 6 39 (22–214) 128 6 48 (68–238)†
QT coefficient of variation (%) 7.2 6 3.0 (1.9–16.7) 6.7 6 2.5 (1.9–13.7) 9.3 6 4.1 (4.5–16.7)‡
*Excluding 46 patients with bundle branch block. †p , 0.05. ‡p , 0.01. Data presented are mean value 6 SD (range).
HR 5 heart rate; QTc 5 corrected QT interval; Pts 5 patients.
Table 3. Mutivariate Analysis of Clinical Variables and QT
Dispersion as Predictors of Death in Patients Awaiting
Heart Transplantation
Hazards Ratio (95% CI)
Age 1.06 (0.97–1.16)
Male gender 2.04 (0.38–10.9)
Ischemic etiology 0.407 (0.11–1.56)
Previous VTs 0.429 (0.10–1.82)
Antiarrhythmic therapy 0.465 (0.06–3.81)
AF 0.503 (0.10–2.56)
QTDISP 6.77 (1.19–38.5)
CI 5 confidence interval; QTDISP 5 QT dispersion; other abbreviations as
in Table 1.
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gender, functional class, history of antiarrhythmic therapy,
previous ventricular tachyarrhythmias or syncope or left ven-
tricular ejection fraction. However, patients in the long
QTDISP group were more likely to have an ischemic etiology
of heart failure than those in the short QTDISP group (p ,
0.05). For the short and long QTCV groups, there was no
significant difference noted in any of these variables, including
the etiology of heart failure. When mutivariate analysis was
performed to assess the relative importance of QTDISP com-
pared with clinical variables as predictors of mortality, only in
the QTDISP group did the 95% CI not overlap unity (Table 3).
Neither long QTDISP nor long QTCV predicted cause-specific
mortality (Table 4). Although QTc itself was not predictive of
mortality, patients who died were more likely to have an
elevated QTc dispersion compared with those who survived the
waiting period (p , 0.05) (Table 2).
Because there are theoretic concerns that including patients
with atrial fibrillation might result in exaggerated measure-
ments of QT dispersion, analyses were performed in which all
patients with atrial fibrillation were excluded. In these analyses
excluding patients with atrial fibrillation, QTDISP and QTCV
were still mortality predictors (p 5 0.025 and p 5 0.002,
respectively). Survival analyses performed only in patients
without atrial fibrillation (Fig. 3A) were similar to those
performed in patients with atrial fibrillation (Fig. 1) with
respect to either cause-specific or all-cause mortality. Similarly,
even when patients with atrial fibrillation were excluded from
analysis, patients with QTDISP .140 ms were more likely to
Figure 2. Effect of interlead variability of the QT interval on survival
in patients awaiting heart transplantation. A, Effect of QTDISP
(defined as the difference between the maximal and minimal QT
intervals on the screening ECG) on survival in patients awaiting heart
transplantation. Patients were dichotomized into two groups: six
patients whose QTDISP exceeded 140 ms (at time 0) or 72 patients
whose QT was #140 ms (at time 0). Elevated QTDISP evaluated as a
continuous variable likewise predicted an increased mortality (see
Results section). B, Effect of QTCV (calculated as 100 3 [standard
deviation of QT intervals]/mean QT interval) on survival in patients
awaiting heart transplantation. Patients were dichotomized into two
groups: 15 patients whose QTCV exceeded 9% (at time 0) or 63
patients whose QT was #9% (at time 0). Elevated QTCV evaluated as
a continuous variable likewise predicted an increased mortality (see
Results section).
Figure 3. Survival in 67 patients without atrial fibrillation who were
placed on a transplant waiting list (at time 0). A, All-cause mortality is
shown, as well as cause-specific mortality. Congestive heart failure and
sudden death were defined as described in the Methods section. B,
Effect of QTDISP, according to the screening ECG, on survival in
patients without atrial fibrillation. The methods are described in the
legend to Figure 2.
Table 4. Overall and Cause-Specific Mortality as a Function of
Interlead Variability of the QT Interval
QTDISP QTCV
Long
(.140 ms)
Short
(#140 ms)
Long
(.9%)
Short
(#9%)
No. of patients 6 72 15 63
Overall mortality 3 11 6 8
Sudden death 2 5 3 4
Heart failure death 1 6 3 4
QTCV 5 coefficient of variation of QT intervals; QTDISP 5 QT dispersion.
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die than those with QTDISP #140 ms while awaiting heart
transplantation (Fig. 3B). When patients with atrial fibrillation
were excluded from analysis, neither clinical, ECG nor
SAECG variables were predictive of either total or cause-
specific mortality during the waiting period.
Signal-averaged ECG measurements. Mean SAECG data
for the 80 patients on the waiting list were: 147 6 31 ms for
fQRS; 27 6 21 mV for V40; and 40 6 21 ms for LAS. This
means that 83% of patients had an abnormal fQRS, and 53%
and 46% of patients had abnormal V40 and LAS, respectively.
Taken together, there was a 45% chance that all three vari-
ables were abnormal, and an 88% chance that at least one
SAECG variable was abnormal. Even when 46 patients with
BBB/IVCD were excluded from the analysis, there was still a
69% chance that at least one SAECG variable was abnormal
(Table 5). No single SAECG variable, or combination thereof,
predicted mortality, even when patients with BBB/IVCD were
excluded from the analysis. However, none of the 10 patients
with a completely normal SAECG died suddenly during the
waiting period. There was no relation between the nature of
the underlying cardiac disease and the presence of SAECG
abnormalities.
Signal-averaged ECG results were not related to the QT
dispersion variables. When at least one SAECG variable was
abnormal compared with the criteria for a normal SAECG,
QTDISP (96 6 52 ms vs. 92 6 67 ms) and QTCV (7.6 6 4.4%
vs. 7.8 6 4.5%) did not differ significantly. Similar results were
present in the subgroup without BBB/IVCD.
Discussion
Overview. These results demonstrate that there is a sub-
stantial mortality risk for patients awaiting heart transplanta-
tion. Nearly 20% of these patients are dead within 6 months,
highlighting the need to identify risk factors at the time of
placement on the waiting list. Because interlead variability of
the QT interval on the ECG provides a noninvasive means for
detecting spatial dispersion of repolarization (32,33), which
may represent a substrate for sudden death, we evaluated the
predictive value of QT dispersion for mortality during the
waiting period before heart transplantation. When QT disper-
sion was measured from a single standard 12-lead ECG, there
was a striking increased mortality risk in those patients with
increased interlead variability of the QT interval measured by
a variety of means. As the measurement of QT dispersion
represents an easy and effective means of identifying those
patients who are likely to die during the waiting period, it may
serve as an important adjunct in the decision regarding priority
for heart transplantation. No clinical or SAECG variable could
predict either total or cause-specific mortality.
QT dispersion as a marker of risk. Of all the risk factors
analyzed in this study, as well as all risk factors studied to date
in a group awaiting heart transplantation, QT dispersion
appears to be the one which best predicts mortality risk during
the waiting period. In this study, there was a 4.1-fold increased
mortality risk for those patients whose QT dispersion exceeded
140 ms, and a 4.1-fold increased mortality in those whose
QTCV was $9%. QT dispersion may identify high risk patients
with a single screening ECG, which can be performed easily,
inexpensively and at sites distant from a major heart transplant
center. This study adds a new dimension to previous reports
indicating the usefulness of QT dispersion as a predictor of
sudden death after myocardial infarction (21) in heart failure
of ischemic etiology (22), as well as arrhythmia risk in the long
QT syndrome (32). It is not surprising to note that values for
both QTDISP (59 6 13 ms [34], 48 6 21 ms [35]) and QTCV
(3.6% [36]) in healthy subjects (with presumably low mortality
risk) reflect lower interlead variability in QT intervals than that
in the patients evaluated in this study (QTDISP 89 6 13 ms
and QTCV 7.2 6 3.0% for all patients evaluated in this study).
Prolongation of the QT interval, per se (in contrast to QT
dispersion), marks cardiovascular risk in many patient cohorts,
including apparently healthy subjects (19), those with alcoholic
cirrhosis (16) and those with coronary artery disease (17).
However, both in our series as well as in others (20,22), QT
prolongation does not mark sudden death risk in patients with
cardiac dysfunction. This is likely to reflect the fact that QT
prolongation does not reflect spatial differences in myocardial
repolarization times (37), which QT dispersion does (32,33).
In addition, sympathetic tone has a strong modulating role
on QT dispersion. Patients with the long QT syndrome treated
with beta-blockade or sympathetic denervation demonstrate a
reduction in QT dispersion (35). This observation is particu-
larly intriguing in light of the current neurohormonal hypoth-
esis of heart failure (38), implicating activation of sympathetic
tone and release of multiple neurohormones (including nor-
epinephrine [10]) in the pathogenesis and progression of heart
failure. Although further investigation is needed, it is possible
that neurohormonal activation in severe heart failure may be
reflected in measurements of QT dispersion, thus conceivably
providing a pathophysiologic connection to overall cardiac
mortality in this condition.
Although total mortality was predicted by measurements of
interlead variability of QT intervals, in our group of patients
with heart failure of diverse etiologies, indices of QT disper-
sion did not predict mechanism of death. Only in one analysis
Table 5. Signal-Averaged Electrocardiographic Characteristics of
Patients Awaiting Heart Transplantation
All Wait-
Listed Pts
(n 5 80)
Survived
(n 5 66)
Died
(n 5 14)
fQRS (ms) 147 6 31 147 6 31 146 6 35
fQRS (ms)* 119 6 17 120 6 16 117 6 22
V40 (mV) 27 6 21 26 6 19 30 6 32
V40* (mV) 38 6 27 36 6 23 45 6 42
LAS (ms) 40 6 21 41 6 22 37 6 15
LAS* (ms) 34 6 14 34 6 15 33 6 10
*Excluding 46 patients (Pts) with bundle branch block. Data presented are
mean value 6 SD. fQRS 5 filtered QRS duration; LAS 5 duration of low
amplitude signal at the terminal portion of the QRS complex; V40 5 voltage of
the terminal 40 ms of the filtered QRS complex.
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(that of the high QTDISP group) did ischemic etiology predict
a high QTDISP (.140 ms), although it did not predict
mortality or mechanism of death. However, when evaluated as
continuous variables, there was a trend toward the highest
indices of QT dispersion in those patients who died suddenly
(QTDISP 126 6 51 ms, 99 6 51 ms and 85 6 34 ms; QTCV
10.0 6 4.3%, 8.6 6 4.0% and 6.7 6 2.5% for patients with
sudden death or heart failure or those who survived, respec-
tively). Although our small sample size precludes a direct
conclusion relating to QT dispersion as predicting mechanism
of death, it is interesting to note that an even smaller study of
41 patients with only ischemic cardiomyopathy (22) showed
that an increased QTDISP predicted higher sudden death risk.
It is possible that sudden death is predicted by QTDISP, but in
our study, the number of end points broken down by cause of
death had insufficient power to detect an association. In
addition, proximate mechanisms of death in heart failure are
often difficult to identify, especially in outpatients. Most of our
patients continued to be cared for by their primary physicians
in a large geographic distribution, further hampering accurate
assignment of mechanism of death. For these reasons, we
chose (a priori) to use cardiac death as our primary end point.
It has become increasingly common for prospective studies to
use overall mortality end points, rather than cause-specific end
points, to avoid bias. Although spatial differences in myocar-
dial repolarization times (reflected by increased QTDISP) (37)
may lead one to predict a higher sudden death risk due to
arrhythmia, QT dispersion does not reflect arrhythmia risk as
assessed by 24-h Holter recording in patients with heart failure
(39).
Our technique of measuring QT intervals from hard copy
ECGs is similar to that described in most studies of QT
dispersion to date (26). Although in our study, no fewer than
six leads were available for analysis, it must be recognized that
when fewer leads are analyzed, one is more likely to obtain a
spuriously low value for QT dispersion, as the true minimal or
true maximal values may be missed (26). Use of QTCV, as
previously described (35,36), serves as a weighted estimate of
interlead variability of all measurable QT intervals. QTCV
takes into account all leads evaluated as a statistical measure
of dispersion, which may account for the slightly improved
potency of QTCV as a mortality predictor compared with
QTDISP (defined as QTmax–QTmin). The cutpoints we have
used in this study to define high and low risk QTDISP and
QTCV groups were established after we had determined that
both measures were strongly predictive of mortality when
evaluated as continuous variables. Although such a post hoc
assignment of high and low risk groups does not weaken the
conclusions derived from an analysis of these continuous
variables, the clinical relevance of the selected cutpoints will
require further study.
Clinical risk factors in the patients studied. The overall
mortality we observed (27%, annualized), as well as its distri-
bution between heart failure and sudden death, is comparable
to that identified in other series of patients awaiting heart
transplantation (4). More relevant to the issue of the wait for
a donor heart, however, was the 12% mortality rate at 3
months and 18% at 6 months. Given the mean wait of nearly
7 months before heart transplantation in this series, similar to
the 6.6-month national average in the United States (3), there
is substantial attrition caused by both heart failure death and
sudden death. This high mortality rate during the waiting
period is particularly disturbing, given the fact that all of the
patients in the current series were deemed appropriate heart
transplant candidates who could have expected improved
quality of life as well as an improved life expectancy (40) had
they survived until the time of heart transplantation.
Evaluation of clinical variables was far less helpful in
stratifying risk in the pretransplant group in our series. Al-
though age evaluated as a continuous variable did not predict
death of patients awaiting heart transplantation, compared
with younger individuals, more older patients (.55 years) died
during the waiting period. Advanced age is already considered
an exclusion criteria for heart transplantation. Some investiga-
tors have suggested that the upper age limit be reduced below
55 years (5). Our data support the concept that older patients
face a greater risk, and that this risk extends to the waiting
period for heart transplantation. In this series, no other clinical
markers of total or cause-specific mortality could be identified.
Although we did note that QT dispersion was elevated in
patients with an ischemic etiology of heart failure, etiology of
heart failure did not predict mortality in our study, commen-
surate with the observations of others (9) that etiology does not
predict mortality in patients with severe heart failure.
Signal-averaged ECG as a marker of risk. The SAECG
has been proposed as a marker of risk of sudden death in a
group of patients who are postmyocardial infarction (41,42),
although it seems to be more useful in predicting serious
arrhythmic events than death in this setting (30,41,43,44). The
SAECG obtained at baseline should reflect the stable conduc-
tion characteristics of the individual patient, regardless of the
degree of decompensation of heart failure (45), and so a single
recording of the SAECG at entry into this study was per-
formed. The present data show that mortality cannot be
predicted by any single SAECG variable or combination
thereof. This may be due in part to the high prevalence of
abnormal SAECGs in this critically ill group of patients (88%
in our series). A completely normal SAECG (12% of trans-
plant candidates), however, was not associated with any in-
stances of sudden death in the present series. This is consistent
with the data of others (11–13,15,30,43), which show that in
both patients with dilated cardiomyopathy or previous myocar-
dial infarction, a normal SAECG is associated with a low risk
of sudden death.
Conclusions. Patients awaiting heart transplantation have
a high risk of dying during the waiting period (nearly 20% at 6
months). No clinical variable at entry (including ejection
fraction) predicted mortality risk in this series. In contrast,
indices of QT dispersion obtained on a single 12-lead ECG
obtained at the time of placement on the waiting list provided
a new means to identify patients at high risk of dying during the
waiting period. Because heart transplantation candidates far
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exceed available donor hearts, transplant waiting lists are
growing at an alarming rate (4), and hearts are preferentially
going to sicker inpatient candidates. Taken together, these
data suggest that elevated QT dispersion (with its high risk of
all-cause mortality) can be used to stratify patients on heart
transplant waiting lists. Creation of such a risk profile would
not only help to establish priority on a transplant waiting list to
optimize allocation of a scarce medical resource, but also
might serve to limit needless deaths of patients who die
awaiting their donor heart.
We thank Arlene Regan and June Ellison for their expert assistance in collecting
data.
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